Short Summary
Apple and Apex Beam have settled their dispute over U.S. Patent 11,374,721 and jointly moved to terminate the inter partes review, citing statutory requirements and public‑policy benefits of settlement.
Detailed Summary
In IPR2025-00901, Apple Inc. and Apex Beam Technologies LLC jointly filed a motion to terminate the inter partes review of U.S. Patent No. 11,374,721, which covers a method and device for wireless communication. The parties submitted a confidential settlement agreement and release, asserting that they have satisfied the statutory conditions of a joint request under 35 U.S.C. §317(a) and (b) before any merits decision. Emphasizing cost savings and public‑policy support for settlements, they asked the Board to end the proceeding. The Board is expected to grant the termination, effectively concluding the dispute.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Apple Inc. vs Apex Beam Technologies LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
HP Inc. et al.vsUniversal Connectivity Technologies Inc.
The PTAB denied the IPR petition filed by HP Inc. and others against Universal Connectivity Technologies Inc., citing that the petitioner's allegations of anticipation and obviousness were not 'particularly strong.' The decision also addressed discretionary denial under § 314(a) based on parallel district court litigation.
Deltran USA LLC et al.vsThe Noco Company
The PTAB granted institution of an IPR against The Noco Company's 11,584,243 B2 jump‑starter patent. The petitioner, Deltran USA LLC, persuaded the Board that at least one claim is likely unpatentable based on obviousness over combinations such as Richardson + Zhao. All eight challenged claims are now subject to trial.
Normshield, Inc. d/b/a Black Kite Inc.vsBitSight Technologies, Inc.
NormShield and BitSight have jointly moved to terminate IPR2025-00276 concerning patent 11,777,976. The parties cite a settlement agreement and argue that early dismissal saves costs and resources.
Menard, Inc.vsSignify Holdings B.V. et al.
The Final Written Decision found that most claims (1-7, 9-15, and 18-20) were unpatentable under § 103 based on prior art combinations. The Board affirmed the Petitioner's success in demonstrating obviousness over references like Chaimberg and Roberge for several claim groups. While some procedural issues regarding timeliness were resolved favorably for the Petitioner, the core finding was a rejection of broad claims due to anticipation and obviousness.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck has filed a PGR petition challenging Halozyme’s 13 claims covering PH20 hyaluronidase variants, asserting lack of written description, enablement, and obviousness. The petition seeks to have the claims declared unpatentable.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.